Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against…

• UD
  U.S. Department of Health and Human Services
• P
  Pfizer
• S
  Sanofi
• YU
  Yale University
• KP
  Kaiser Permanente
• PO
  Patient-Centered Outcomes Research Institute
• VU
  Vanderbilt University
• UD
  Utah Department of Health
• UO
  University of Miami
• EU
  Emory University
• WF
  Wake Forest University
• CC
  Cleveland Clinic
• BU
  Baylor University
• UO
  University of Washington
• JH
  Johns Hopkins University

  Award: COVID-19
• HC
  Hennepin County Medical Center
• IU
  Indiana University Health
• VU
  Vanderbilt University Medical Center
• M
  Moderna
• S
  Seqirus
• NI
  National Institutes of Health

  Award: COVID-19
• CF
  Centers for Disease Control and Prevention
• SO
  School of Medicine, Stanford University
• UO
  University of California, Los Angeles
• KF
  Kaiser Foundation Research Institute
• WF
  Wake Forest School of Medicine
• SO
  School of Medicine, Indiana University
• BU
  Baylor University Medical Center
• IM
  Irving Medical Center, Columbia University
• SP
  Sanofi Pasteur
• NC
  National Center for Immunization and Respiratory Diseases
• UO
  University of Colorado School of Medicine, Anschutz Medical Campus